Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: When Suffering Is Multiplied.

Komaroff, Anthony L · Healthcare (Basel, Switzerland) · 2021 · DOI

Quick Summary

ME/CFS is a real illness with measurable biological problems in the body, even though standard blood tests often appear normal. Over the past 20 years, advanced research tools have found objective abnormalities in people with ME/CFS. Unfortunately, many doctors aren't aware of this evidence, which can lead them to dismiss patients' symptoms and wrongly suggest there's nothing physically wrong—adding emotional harm on top of the already serious illness.

Why It Matters

This work addresses a critical gap between scientific evidence and clinical practice—many doctors remain unaware of documented biological abnormalities in ME/CFS, leading to harmful dismissal of patients. By highlighting objective research findings, the editorial advocates for validation of patient suffering and improved clinical recognition. This bridging of the evidence-practice gap is essential for reducing diagnostic delay, inappropriate psychiatric labeling, and the compounded suffering patients experience.

Observed Findings

Advanced research technologies have uncovered multiple biological abnormalities in ME/CFS populations over the past 20 years
Routine clinical laboratory tests often return normal results despite presence of objective abnormalities detectable by specialized research methods
Many physicians remain unaware of the body of evidence documenting biological abnormalities in ME/CFS
Physician skepticism and dismissal of ME/CFS as a legitimate physical illness compounds patient suffering beyond the primary disease burden

Inferred Conclusions

ME/CFS is a biomedically grounded illness with objective abnormalities, not a primarily psychiatric or psychosomatic condition
Physician education and awareness of recent biomedical research findings is necessary to reduce diagnostic bias and delegitimization
The gap between scientific evidence and clinical practice contributes significantly to patient suffering through iatrogenic harm
Validation of biological abnormalities is essential for appropriate clinical recognition and improved patient outcomes

Remaining Questions

Which of the identified biological abnormalities are primary disease drivers versus secondary manifestations or compensatory responses?
Which specific biomarkers or objective tests should be integrated into routine clinical practice for diagnosis and disease monitoring?
What are the most effective strategies to educate and update physician knowledge about ME/CFS biology to change clinical practice patterns?
How do different biological abnormalities correlate with symptom severity, disease subtypes, and prognosis in ME/CFS?

What This Study Does Not Prove

This editorial does not provide new experimental data or identify the specific biological mechanisms causing ME/CFS. It does not establish which abnormalities are disease-causing versus secondary consequences, nor does it prove that awareness alone will change clinical practice. The paper reviews existing research but does not systematically quantify the prevalence or clinical utility of identified abnormalities.

Topics

Biomarkers

Metadata

DOI: 10.3390/healthcare9070919
PMID: 34356297
Review status: Machine draft
Evidence level: Early hypothesis, preprint, editorial, or weak support
Last updated: 7 April 2026